Business
DCF100 Skin Study Results
DCF100 Skin Study Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n Futura Medical PLC\n06 September 2006\n\n\n\n\nFor immediate release 6 September 2006\n\n\n\n Futura Medical Plc\n\n\n\n New topical analgesics formulation\n beats leading brands in human skin studies\n\n\n\nFutura Medical plc (AIM: FUM) the pharmaceutical and medical device group, today\nannounces that its new topical non-steroidal anti-inflammatory (NSAID)\nformulation, known as DCF100, has shown impressive results in recently conducted\nin vitro human skin permeation studies with permeation rates in excess of eight\ntimes higher than the world's current market leader.\n\n\n\nPermeation through human abdominal skin was measured in a validated model for a\nvariety of formulations in studies conducted by Professor Mike Roberts at the\nUniversity of Queensland in Australia. Professor Roberts is a world-renowned\nexpert in skin permeability of pharmaceutical compounds.\n\n\n\nThe dramatic improvement in permeation rates observed in DCF100 formulations\ncompared with two over the counter topical brands, including the world's market\nleader, Voltarol(R) Emulgel, is highlighted in a graph viewable at http://\nwww.futuramedical.co.uk/archive/060906_graph.pdf DCF100 also showed a\nstatistically significant improvement in drug delivered through the skin in a 24\nhour period from a single dose compared with Pennsaid(R), a prescription based\ntopical NSAID which up until now has provided the best reported permeation rates\nfor topical Diclofenac.\n\n\n\nVoltarol(R) Emulgel worldwide topical sales are estimated to be US$215 million\nout of a current worldwide market for topical NSAIDs in 2005 of US$2.35 billion.\n No topical NSAID has yet received marketing authorisation within the USA from\nthe Food and Drug Administration (FDA). This is due to concerns that NSAIDs\ncannot permeate the skin in sufficient quantity to deliver a therapeutic dose.\nThis may however change with the regulatory dossier on Pennsaid(R) recently\nbeing submitted to the FDA to obtain marketing authorisation due to its improved\nskin permeation compared with existing topical NSAIDs. We expect the market for\ntopical NSAIDs to grow significantly once the FDA approves products.\n\n\n\nPlans are at an advanced stage to conduct human tissue micro-dialysis and plasma\nlevel studies later this year with Futura's preferred DCF100 formulation. These\nstudies aim to confir...